Pritelivir - AiCuris
Alternative Names: AIC-316; BAY 57-1293Latest Information Update: 24 Apr 2026
At a glance
- Originator Bayer
- Developer AiCuris
- Class Acetamides; Amides; Antivirals; Benzyl compounds; Pyridines; Small molecules; Sulfonamides; Thiazoles
- Mechanism of Action DNA helicase-primase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Herpes simplex virus infections
- Phase II Herpes labialis; Herpes simplex virus type 2 infections
Most Recent Events
- 16 Apr 2026 Preregistration for Herpes simplex virus infections (Treatment-resistant) in USA (PO)
- 16 Apr 2026 The US FDA sets a Prescription Drug User Fee Act (PDUFA) Target Date for NDA review in the fourth quarter of 2026
- 16 Apr 2026 Efficacy data from a phase III PRIOH-1 trial in Herpes simplex virus infections released by AiCuris